Lilly has reported comprehensive outcomes from the Phase III trial of tirzepatide for individuals with heart failure with ...

GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia ...

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma ...

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases ...

The pathology and radiology giant is recovering from its post-pandemic malaise and says earnings should improve this year ...

Basel, November 19, 2024 – Novartis has ranked first in the 2024 Access to Medicine Index (ATMI) report published today, highlighting the company’s leadership in improving access to medicines around ...

Ocugen (NASDAQ:OCGN) reported positive Phase 1 data for its gene therapy candidate OCU410 in the treatment of geographic ...

Annual BioTech Breakthrough Award is devoted to honoring excellence in life science and biotechnology solutions, services, ...

One study seeks to identify biomarkers that could be used to identify horses at high risk of EASD, while the other focuses on ...

With FDA approval in the bag for its AI-based aortic stenosis diagnostic tool, Echo IQ is focused on commercialisation over the coming years.

Acquired factor V (FV) inhibitors are extremely rare and present with a broad spectrum ranging from asymptomatic laboratory anomalies to life-threatening critical bleeds. The overall rarity along with ...

Johnson & Johnson (J&J) has reported positive topline outcomes from its Phase III ICONIC-LEAD trial of oral icotrokinra ...